Combined hormonal contraceptives containing 20 μg EE and 75 μg GSD is tested in clinical practice, reliable
contraception, popular in gynecologists and users. With metabolic neutrality, minimum impact on body weight
changes, a good control of cycle and sufficient antiandrogenic effect is a basis for the development of a new contraceptive
patch. Lisvy patch releases 13μg of EE and 60μg GSD per 24 hours. The average daily doses of EE and
GSD released from Lisvy over the 7-day application period provided the same systemic exposure as those observed
following daily administration of COC containing 20μg EE and GSD.The patch has a chance to expand the
number of users of hormonal contraception, especially those where compliance is reduced consists in forgetting
regular intake of tablets.